Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.

NCT00171145 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00171145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00171145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2004
Completion date
December 31, 2004
Enrollment
445 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder syndrome